辛伐他汀片对透析合并脑卒中患者氧化应激状态及疗效的影响

Effect of simvastatin on hemodialysis complicated with cerebral apoplexy patients＇ oxidative stress state

目的观察辛伐他汀片对透析合并脑卒中患者氧化应激状态的影响及临床疗效。方法透析患者合并脑卒中190例，随机分为治疗组：服用辛伐他汀片（20mg／d）和对照组：不服用辛伐他汀片。2组又分为静脉血液透析（hemodialysis，HD）组与静脉腹膜透析（peritonealdialysis，PD）组。总疗程2周，检测2组患者治疗前后血浆同型半胱氨酸（Homocysteine，HCY）水平，观察2组临床疗效、神经功能缺损评分情况。结果治疗组治疗1周时HCY与治疗前无明显变化，无统计学意义（P〉0．05），2周时血浆HCY明显低于对照组，差异有统计学意义俨〈0．05）；治疗后治疗组评分明显低于对照组（P〈0．05），HD组与PD组与神经功能缺损评分差异无统计学意义（P〉0．05）。结论辛伐他汀可通过减轻透析合并脑卒中患者的氧化应激状态而达到改善神经功能缺损及日常生活能力的目的。

Objective To observe the effect of simvastatin on hemodialysis complicated with cerebral apoplexy patients＇ oxidative stress state and curative effect. Methods 190 cases of hemodialysis patients with cerebral stroke were randomly divided into the treatment group that took simvastatin tablet （20mg/d）, and control group that did not take simvastatin tablet. Then each group was divided into venous hemodialysis （hemodialysis, HD） group and intravenous peritoneal dialysis （peritoneal dialysis, PD） group. In the two-week of treatment, the plasma homocysteine （Homocysteine, HCY） level, clinical, and neurological deficit scores were compared before and after the treatment between the two groups. Results The HCY reflected no significant change on the treatment group after one-week treatment comparing with that prior to the treatment （P 〉0.05）; after the two-week treatment, the plasma HCY reflected significantly lower than that of the control group with statistical difference （P 〈0.05）; The index scores of the treatment group were significantly lower than that of control group after the treatment （ P 〈0.05）; No significant difference on nervous function defect score was found between HD group and PD group （P 〉0.05）. Conclusion Simvastatin can improve neural function defect and the ability of daily life through reducing hemodialysis complicated with cerebral apoplexy patients＇ oxidative stress state.